HUP0001917A2 - Sclerosis multiplex kezelése kopolimer-1 bevételével vagy inhalálásával - Google Patents

Sclerosis multiplex kezelése kopolimer-1 bevételével vagy inhalálásával

Info

Publication number
HUP0001917A2
HUP0001917A2 HU0001917A HUP0001917A HUP0001917A2 HU P0001917 A2 HUP0001917 A2 HU P0001917A2 HU 0001917 A HU0001917 A HU 0001917A HU P0001917 A HUP0001917 A HU P0001917A HU P0001917 A2 HUP0001917 A2 HU P0001917A2
Authority
HU
Hungary
Prior art keywords
copolymer
ingestion
inhalation
treatment
multiple sclerosis
Prior art date
Application number
HU0001917A
Other languages
English (en)
Inventor
Ruth Arnon
Adrian Gilbert
Milka Linenberg
Rivka Riven-Kreitman
Michael Sela
Dvora Teitelbaum
Original Assignee
Yeda Research And Development Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research And Development Co., Ltd. filed Critical Yeda Research And Development Co., Ltd.
Publication of HUP0001917A2 publication Critical patent/HUP0001917A2/hu
Publication of HUP0001917A3 publication Critical patent/HUP0001917A3/hu
Publication of HU226612B1 publication Critical patent/HU226612B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Abstract

A találmány sclerosis multiplex kezelésére vonatkozik kopolimer-1bevételével vagy inhalálásával. A kopolimer-1 Copaxone kereskedelminéven van forgalomban, és L-glutamin-savat, L-alanint, L-tirozint ésL-lizint tartalmazó polipeptidek acetát-sóiból áll. A találmánytárgyát képezi kopolimer-1-et tartalmazó, sclerosis multiplexkezelésére alkalmas gyógyászati készítmény is, amely bevételre vagyinhalálásra szánt alakban van. Ó
HU0001917A 1997-01-10 1998-01-12 Use of glatiramer acetate for production of pharmaceutical composition to the treatment of multiple sclerosis HU226612B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL11998997A IL119989A0 (en) 1997-01-10 1997-01-10 Pharmaceutical compositions for oral treatment of multiple sclerosis
PCT/US1998/000375 WO1998030227A1 (en) 1997-01-10 1998-01-12 Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1

Publications (3)

Publication Number Publication Date
HUP0001917A2 true HUP0001917A2 (hu) 2000-10-28
HUP0001917A3 HUP0001917A3 (en) 2001-12-28
HU226612B1 HU226612B1 (en) 2009-04-28

Family

ID=11069682

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0001917A HU226612B1 (en) 1997-01-10 1998-01-12 Use of glatiramer acetate for production of pharmaceutical composition to the treatment of multiple sclerosis

Country Status (19)

Country Link
EP (1) EP0975351B1 (hu)
JP (1) JP4216342B2 (hu)
KR (1) KR20000070058A (hu)
CN (1) CN100528222C (hu)
AT (1) ATE356608T1 (hu)
AU (1) AU737287B2 (hu)
BR (1) BRPI9807076B8 (hu)
CA (1) CA2277365C (hu)
CZ (1) CZ297983B6 (hu)
DE (1) DE69837324T2 (hu)
EA (1) EA003128B1 (hu)
HK (1) HK1025737A1 (hu)
HU (1) HU226612B1 (hu)
IL (2) IL119989A0 (hu)
NZ (1) NZ336690A (hu)
PL (1) PL193300B1 (hu)
SK (1) SK284029B6 (hu)
WO (1) WO1998030227A1 (hu)
ZA (1) ZA98214B (hu)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2527760T3 (es) 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
EP1105414A2 (en) * 1998-07-23 2001-06-13 President And Fellows of Harvard College Synthetic peptides and methods of use for autoimmune disease therapies
WO2000005250A1 (en) 1998-07-23 2000-02-03 Yeda Research And Development Co., Ltd Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides
US6800287B2 (en) 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
PT1187612E (pt) * 1999-06-04 2005-05-31 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Utilizacao do riluzole para o tratamento da esclerose multipla
DE60041365D1 (de) * 1999-06-04 2009-02-26 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Verwendung von Riluzol zur Behandlung Multipler Sklerose
JP2003522799A (ja) * 2000-02-18 2003-07-29 イエダ・リサーチ・アンド・ディベロップメント・カンパニー・リミテッド・アット・ザ・ウェイズマン・インスティテュート・オブ・サイエンス コポリマー１の経口、経鼻および経肺投与製剤
US7022663B2 (en) 2000-02-18 2006-04-04 Yeda Research And Development Co., Ltd. Oral, nasal and pulmonary dosage formulations of copolymer 1
US20020077278A1 (en) 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
IL153236A0 (en) * 2000-06-05 2003-07-06 Teva Pharma The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
WO2002076503A1 (en) 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
PT1459065E (pt) 2001-12-04 2010-10-11 Teva Pharma Processos para a medição da potência do acetato de glatirâmero
PT2336184E (pt) 2002-02-25 2015-03-09 Biogen Idec Inc Administração de agentes para o tratamento da inflamação
EP1592387A4 (en) * 2003-01-24 2009-05-06 Elan Pharm Inc COMPOSITION AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
DK1797109T3 (en) 2004-09-09 2016-04-11 Yeda Res & Dev MIXTURES OF POLYPEPTIDES, compositions containing them and methods for their preparation, and uses thereof
DE202010018377U1 (de) 2009-08-20 2016-02-25 Yeda Research And Development Co., Ltd. Niedrigfrequente therapie mit glatirameracetat
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
EA025780B1 (ru) 2010-10-11 2017-01-30 Тева Фармасьютикал Индастриз Лтд. Цитокиновые биомаркеры в качестве биомаркеров, прогнозирующих клинический ответ на глатирамер ацетат
KR20140101730A (ko) 2011-10-10 2014-08-20 테바 파마슈티컬 인더스트리즈 리미티드 글라티라머 아세테이트에 대한 임상 반응을 예측하는 데 유용한 단일 뉴클레오티드 다형성
US9617596B2 (en) 2012-10-10 2017-04-11 Teva Pharmaceutical Industries, Ltd. Biomarkers predictive for clinical response for glatiramer acetate
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
CN105884866B (zh) * 2015-01-26 2021-04-20 漳州未名博欣生物医药有限公司 格拉替雷的化学合成方法
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
CN112649538B (zh) * 2015-04-28 2024-03-29 深圳翰宇药业股份有限公司 多肽混合物高效液相色谱分析方法
WO2018178973A1 (en) 2017-03-26 2018-10-04 Mapi Pharma Ltd. Glatiramer depot systems for treating progressive forms of multiple sclerosis
US10323289B2 (en) 2017-06-26 2019-06-18 Institut Pasteur Treatments to eliminate HIV reservoirs and reduce viral load

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800808A (en) * 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
US5719296A (en) * 1995-10-30 1998-02-17 Merck & Co., Inc. Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins

Also Published As

Publication number Publication date
SK93199A3 (en) 2000-11-07
EA199900621A1 (ru) 2000-02-28
CN1249690A (zh) 2000-04-05
WO1998030227A1 (en) 1998-07-16
SK284029B6 (sk) 2004-08-03
AU5819598A (en) 1998-08-03
KR20000070058A (ko) 2000-11-25
EA003128B1 (ru) 2003-02-27
CA2277365C (en) 2011-04-12
ATE356608T1 (de) 2007-04-15
DE69837324T2 (de) 2007-11-29
EP0975351B1 (en) 2007-03-14
AU737287B2 (en) 2001-08-16
BR9807076B1 (pt) 2013-10-29
HU226612B1 (en) 2009-04-28
HUP0001917A3 (en) 2001-12-28
PL334566A1 (en) 2000-03-13
PL193300B1 (pl) 2007-01-31
NZ336690A (en) 2001-05-25
ZA98214B (en) 1999-08-11
BR9807076A (pt) 2000-05-02
DE69837324D1 (de) 2007-04-26
CZ243799A3 (cs) 2000-06-14
EP0975351A1 (en) 2000-02-02
IL130820A (en) 2007-03-08
HK1025737A1 (en) 2000-11-24
BRPI9807076B8 (pt) 2021-05-25
IL119989A0 (en) 1997-04-15
JP2001511121A (ja) 2001-08-07
EP0975351A4 (en) 2002-05-15
CN100528222C (zh) 2009-08-19
CZ297983B6 (cs) 2007-05-16
JP4216342B2 (ja) 2009-01-28
CA2277365A1 (en) 1998-07-16

Similar Documents

Publication Publication Date Title
HUP0001917A2 (hu) Sclerosis multiplex kezelése kopolimer-1 bevételével vagy inhalálásával
FI945912A0 (fi) Proteinoidikantajat ja menetelmät niiden valmistamiseksi sekä niiden käyttö
HUP9702307A2 (hu) Antigén kibocsátásra alkalmas készítmény
CA2329005A1 (en) Folic acid-containing pharmaceutical compositions, and related methods and delivery systems
DE69531741D1 (de) Verbindungen und zusammensetzungen zur verabreichung aktiver stoffe
AU6819294A (en) Oral drug delivery compositions and methods
NZ512866A (en) A nutritional composition comprising at least one tolerogenic peptide, selected for its ability to induce oral tolerance, as an active ingredient
ES2099022A1 (es) Composiciones farmaceuticas que contienen las sales de acido s(+)-2-(4-isobutilfenil) propionico con aminoacidos basicos.
IS2034B (is) Ný lyfjablanda til inntöku um munn sem inniheldurnýtt magnesíumsalt ómeprasóls, aðferð við framleiðslu hennar og notkun
BR9906920A (pt) "tts contendo um antioxidante"
HUP0103883A2 (hu) Új, késleltetett felszabadulású, orális készítmények
ATE493998T1 (de) Pharmazeutische zusammensetzung mit einem exendin-4-peptid
ATE302588T1 (de) Dentales produkt gegen zahnstein und betreffende methode
CA2233457A1 (en) Pharmaceutical angiostatic dipeptide compositions and methods of use thereof
TR199901132T2 (xx) N-(aril/heteoaril) amino asit t�revleri, bunlar� i�eren farmas�tik bile�imler ve b�yle bile�ikler kullan�larak �-amiloid peptidinin sal�nmas�n� ve/veya sentezini inhibe etmek i�in y�ntemler.
HUP9801227A2 (hu) Monoamin-oxidáz B inhibitorokból álló gyógyászati készítmények és alkalmazásuk
ATE171869T1 (de) Film zur lokalen arzneistoffabgabe für periodontale behandlung
DE69617395T2 (de) Pharmazeutische zusammensetzungen enthaltent ein superoxyddismutase
HUP0302333A3 (en) The use of glatiramer acetate (copolymer 1) for the preparation of pharmaceutical compositions available in the treatment of central nervous system disorders
ATE215817T1 (de) Feste miltefosin enthaltende arzneimittel zur oralen verabreichung bei der behandlung von leishmaniasis
HUP0001084A2 (hu) 5-ASA-t tartalmazó, módosított hatóanyag-felszabadulást biztosító orális gyógyászati készítmény bélbetegségek kezelésére
HUP0301128A2 (hu) 5-Metil-2-(2'-kloro-6'-fluoranilino)-fenilecetsavat tartalmazó gyógyszerkészítmények ciklooxigenáz-2-vel kapcsolatos betegségek kezelésére és alkalmazásuk
EP0855181A3 (en) Medicament or nutritional formulation for immune-modulation with amino acids
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
PL315619A1 (en) Oral form of a drug containing acid active substances and method of obtaining same